D Laurent
Overview
Explore the profile of D Laurent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
232
Citations
2475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Darius H, Drescher O, Ponton D, Pawlowiez R, Laurent D, Dewailly E, et al.
Food Addit Contam Part A Chem Anal Control Expo Risk Assess
. 2013 Jan;
30(3):550-66.
PMID: 23289800
Ciguatera fish poisoning is a seafood intoxication commonly afflicting island communities in the Pacific. These populations, which are strongly dependent on fish resources, have developed over centuries various strategies to...
12.
Giatromanolaki A, Koukourakis M, Sivridis E, Gatter K, Trarbach T, Folprecht G, et al.
Br J Cancer
. 2012 Aug;
107(7):1044-50.
PMID: 22910317
Background: Pharmacological inhibitors of vascular endothelial growth factor (VEGF) receptors, like vatalanib, have been tested in randomised trials (CONFIRM (Colorectal Oral Novel therapy For the Inhibition of Angiogenesis and Retarding...
13.
Schopfer K, Rieder H, Bodmer T, Steinlin-Schopfer J, Chantana Y, Somathea T, et al.
Int J Tuberc Lung Dis
. 2012 Feb;
16(4):503-9.
PMID: 22326031
Setting: Tuberculosis laboratory in the Jayavarman VII Children's Hospital in Siem Reap, part of the Kantha Bopha Hospitals, the largest pediatric hospital complex in Cambodia. Objective: To determine the efficiency...
14.
Abellan van Kan G, Cderbaum J, Cesari M, Dahinden P, Fariello R, Fielding R, et al.
J Nutr Health Aging
. 2011 Dec;
15(10):834-46.
PMID: 22159770
No abstract available.
15.
Gauler T, Besse B, Mauguen A, Meric J, Gounant V, Fischer B, et al.
Ann Oncol
. 2011 May;
23(3):678-687.
PMID: 21617019
Background: The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth...
16.
Joensuu H, de Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, et al.
Br J Cancer
. 2011 May;
104(11):1686-90.
PMID: 21540861
Background: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of...
17.
Riccio R, Greco O, Minale L, La Barre S, Laurent D
J Nat Prod
. 2011 Mar;
51(5):1003-5.
PMID: 21401195
No abstract available.
18.
19.
Laurent D, Gounarides J, Gao J, Boettcher B
Diabetes Obes Metab
. 2009 Jan;
11(6):632-6.
PMID: 19175377
Aim: By acting as both insulin sensitizers and lipid-lowering agents, dual-acting peroxisome proliferator-activated receptors alpha/gamma (PPARalpha/gamma) agonists may be used to improve glucose tolerance in type 2 diabetic patients without...
20.
Joensuu H, de Braud F, Coco P, De Pas T, Putzu C, Spreafico C, et al.
Ann Oncol
. 2007 Aug;
19(1):173-7.
PMID: 17698976
Background: We evaluated safety and efficacy of PTK787/ZK222584 (PTK/ZK), a novel tyrosine kinase inhibitor of KIT, platelet-derived growth factor receptors and vascular endothelial cell growth factor receptors (VEGFRs), in patients...